JP2023100869A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023100869A5 JP2023100869A5 JP2023076848A JP2023076848A JP2023100869A5 JP 2023100869 A5 JP2023100869 A5 JP 2023100869A5 JP 2023076848 A JP2023076848 A JP 2023076848A JP 2023076848 A JP2023076848 A JP 2023076848A JP 2023100869 A5 JP2023100869 A5 JP 2023100869A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- urolithin
- composition
- salt
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 27
- RIUPLDUFZCXCHM-UHFFFAOYSA-N Urolithin A Chemical compound OC1=CC=C2C3=CC=C(O)C=C3OC(=O)C2=C1 RIUPLDUFZCXCHM-UHFFFAOYSA-N 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 11
- 210000003205 muscle Anatomy 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000002207 metabolite Substances 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims 3
- 229960004203 carnitine Drugs 0.000 claims 3
- 235000015872 dietary supplement Nutrition 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000008437 mitochondrial biogenesis Effects 0.000 claims 3
- 230000004220 muscle function Effects 0.000 claims 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 3
- 230000002715 bioenergetic effect Effects 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000036119 Frailty Diseases 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 235000012041 food component Nutrition 0.000 claims 1
- 239000005417 food ingredient Substances 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000036284 oxygen consumption Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1703735.9 | 2017-03-08 | ||
| GBGB1703735.9A GB201703735D0 (en) | 2017-03-08 | 2017-03-08 | Methods for improving mitophagy in subjects |
| GBGB1706594.7A GB201706594D0 (en) | 2017-04-25 | 2017-04-25 | Methods for improving mitophagy in subjects |
| GB1706594.7 | 2017-04-25 | ||
| GBGB1707861.9A GB201707861D0 (en) | 2017-05-16 | 2017-05-16 | Methods for improving mitophagy in subjects |
| GB1707861.9 | 2017-05-16 | ||
| JP2019548663A JP7761371B2 (ja) | 2017-03-08 | 2018-03-08 | 対象におけるマイトファジーを改善するための方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548663A Division JP7761371B2 (ja) | 2017-03-08 | 2018-03-08 | 対象におけるマイトファジーを改善するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023100869A JP2023100869A (ja) | 2023-07-19 |
| JP2023100869A5 true JP2023100869A5 (https=) | 2024-03-06 |
Family
ID=61691936
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548663A Active JP7761371B2 (ja) | 2017-03-08 | 2018-03-08 | 対象におけるマイトファジーを改善するための方法 |
| JP2023076848A Pending JP2023100869A (ja) | 2017-03-08 | 2023-05-08 | 対象におけるマイトファジーを改善するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548663A Active JP7761371B2 (ja) | 2017-03-08 | 2018-03-08 | 対象におけるマイトファジーを改善するための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20180256538A1 (https=) |
| EP (2) | EP4553071A3 (https=) |
| JP (2) | JP7761371B2 (https=) |
| WO (1) | WO2018162650A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4233858T3 (da) | 2012-06-27 | 2025-05-12 | Amazentis Sa | Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse |
| US20180256471A1 (en) * | 2017-03-08 | 2018-09-13 | Amazentis Sa | Skin Treatment Methods |
| JP7761372B2 (ja) * | 2017-03-08 | 2025-10-28 | アマゼンティス エスアー | 対象におけるマイトファジーを改善するための方法 |
| US20230041432A1 (en) * | 2019-03-21 | 2023-02-09 | Fonterra Co-Operative Group Limited | Compositions comprising polar lipids for maintaining or increasing mobility and vitality |
| CA3150587A1 (en) * | 2019-09-25 | 2021-04-01 | Societe Des Produits Nestle S.A. | Compositions and methods using adenosylcobalamin |
| GB201916046D0 (en) * | 2019-11-04 | 2019-12-18 | Amazentis Sa | Diagnostic method |
| EP4065102A1 (en) * | 2019-11-27 | 2022-10-05 | Société des Produits Nestlé S.A. | Benzocoumarin ampk activator compounds, compositions, methods and uses thereof |
| JP2023503276A (ja) * | 2019-11-27 | 2023-01-27 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | Ａｍｐｋ間接活性化化合物と組み合わせたａｍｐｋ直接活性化化合物、組成物、方法、及びそれらの使用 |
| CA3206062A1 (en) * | 2021-01-27 | 2022-08-04 | Said Oumouch | Urolithin derivatives and methods of use thereof |
| EP4085906A1 (en) * | 2021-05-06 | 2022-11-09 | Universite De Bordeaux | Composition comprising ppar-modulator and an urolithin derivative and uses thereof |
| US20240307320A1 (en) * | 2021-07-08 | 2024-09-19 | Biophagy, Inc. | A System and Method for Measuring and Stimulating Autophagy |
| KR102677423B1 (ko) * | 2021-09-17 | 2024-06-21 | 조선대학교산학협력단 | 망기페린을 포함하는 자가포식 활성화용 조성물 |
| EP4452259A1 (en) * | 2021-12-20 | 2024-10-30 | Société des Produits Nestlé S.A. | Compositions comprising urolithin for treating muscle decline and a kidney dysfunction |
| JP2025510123A (ja) | 2022-03-22 | 2025-04-14 | アマゼンティス エスアー | 組成物 |
| CN115607671A (zh) * | 2022-10-26 | 2023-01-17 | 深圳大学 | 一种提高运动皮层尿石素a浓度的方法及应用 |
| EP4712958A2 (en) * | 2023-05-18 | 2026-03-25 | Vandria SA | Use of urolithin derivatives in the treatment of amyotrophic lateral sclerosis |
| GB202308224D0 (en) | 2023-06-01 | 2023-07-19 | Amazentis Sa | Formulation |
| GB202319994D0 (en) | 2023-12-22 | 2024-02-07 | Amazentis Sa | Compositions for use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004073612A2 (en) * | 2003-02-13 | 2004-09-02 | Merck & Co. Inc. | Estrogen receptor modulators |
| WO2009137859A1 (en) * | 2008-05-15 | 2009-11-19 | Alois Jungbauer | Compounds for the treatment of metabolic syndrome and insulin resistance |
| JP6054301B2 (ja) * | 2010-12-23 | 2017-01-11 | アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ | ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法 |
| DK4233858T3 (da) * | 2012-06-27 | 2025-05-12 | Amazentis Sa | Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse |
| GB201323008D0 (en) * | 2013-12-24 | 2014-02-12 | Amazentis As | Compounds and uses thereof |
| GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| JP7761372B2 (ja) * | 2017-03-08 | 2025-10-28 | アマゼンティス エスアー | 対象におけるマイトファジーを改善するための方法 |
| US20180256471A1 (en) * | 2017-03-08 | 2018-09-13 | Amazentis Sa | Skin Treatment Methods |
-
2018
- 2018-03-08 US US15/915,773 patent/US20180256538A1/en not_active Abandoned
- 2018-03-08 EP EP25165087.5A patent/EP4553071A3/en active Pending
- 2018-03-08 EP EP18712106.6A patent/EP3592424A1/en active Pending
- 2018-03-08 WO PCT/EP2018/055788 patent/WO2018162650A1/en not_active Ceased
- 2018-03-08 JP JP2019548663A patent/JP7761371B2/ja active Active
-
2023
- 2023-05-08 JP JP2023076848A patent/JP2023100869A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023100869A5 (https=) | ||
| JP2023100870A5 (https=) | ||
| US10292952B2 (en) | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis | |
| ES3013603T3 (en) | A composition for weight loss or weight management comprising beta-hydroxybutyrate and cannabidiol | |
| KR100545630B1 (ko) | 필수 지방산과 생물활성 이황화물을 함유하는 치료 및식이요법 조성물 | |
| EP2976073B1 (en) | Compositions and methods for producing elevated and sustained ketosis | |
| US6346519B1 (en) | Method and composition for treating arthritis | |
| JPS61277618A (ja) | 自閉症治療剤 | |
| JP2020514338A5 (https=) | ||
| JP2020510678A5 (https=) | ||
| PT1187603E (pt) | ''terapia de associação para promover a perda de peso e o tratamento da obesidade'' | |
| CN110730659B (zh) | 用于提高l-dopa治疗功效的组合物 | |
| US20100331415A1 (en) | Use of omega-3-fatty acid(s) | |
| AU2012272731A1 (en) | Compositions and methods for treatment of chronic fatigue | |
| US20100179089A1 (en) | Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly | |
| AU2012382949A1 (en) | Compositions and methods for treatment of neuropsychological deficits | |
| US20200360322A1 (en) | Formulations and dosage forms for enhancing performance or recovery from stress | |
| US8435963B2 (en) | Weight loss compositions and uses thereof | |
| JP2023535067A (ja) | ヒトにおける呼吸器疾患の治療及び／又は予防のためのβ－ヒドロキシブチレート及び関連化合物の投与 | |
| US20060270625A1 (en) | Nutraceuticals for the treatment of neuropathy | |
| US20100255088A1 (en) | Method for delivering a combination of resveratrol and aspirin for use in treatment and prevention of vascular disease | |
| CN111000862A (zh) | 靶向线粒体逆转早早期癌症的药物组合物及其应用 | |
| US11980601B2 (en) | Compositions and methods for treatment of diabetic neuropathies | |
| WO2019117820A1 (en) | L-enantiomer 2-ethyl-6-methyl-3-hydroxypyridinium l-hydroxybutandioate with cerebroprotective, hepatoprotective, lipid-regulating, anti-ischemic and neurotropic activities | |
| KR101086895B1 (ko) | 시부트라민 및 티옥트산을 포함하는 약제학적 조성물 |